bluebird bio announces long-term data from CALD gene therapybluebird bio has announced new clinical trial data from its gene therapy for patients with cerebral adrenoleukodystrophy (CALD), Share Xbluebird bio announces long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-announced-long-term-data-from-cald-gene-therapy/
bluebird seeks gene therapy trial restart after cancer scarebluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after Share Xbluebird seeks gene therapy trial restart after cancer scarehttps://pharmaphorum.com/news/bluebird-seeks-gene-therapy/
Zynteglo halt re-ignites viral vector safety concerns; analystsBluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of Share XZynteglo halt re-ignites viral vector safety concerns; analystshttps://pharmaphorum.com/news/zynteglo-halt-re-ignites-viral-vector-safety-concerns-analysts/
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyIt’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its Share Xbluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-bio-baffled-after-nice-rejects/
bluebird bio to split into oncology and gene therapy specialistsUS biotech bluebird bio has announced plans to split into two this year, with a separate oncology business Share Xbluebird bio to split into oncology and gene therapy specialistshttps://pharmaphorum.com/news/bluebird-bio-to-split-into-oncology-and-gene-therapy-specialists/
Bluebird trumpets long-term data from beta-thalassaemia gene therapybluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as Share XBluebird trumpets long-term data from beta-thalassaemia gene therapyhttps://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/
EMA starts rapid review of Bluebird’s gene therapy for rare disease CALDBluebird bio could be just a few months away from approval of its gene therapy for rare disease Share XEMA starts rapid review of Bluebird’s gene therapy for rare disease CALDhttps://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/
BMS ‘bet’ with Celgene shareholders in balance after CAR-T refileBristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a Share XBMS ‘bet’ with Celgene shareholders in balance after CAR-T refilehttps://pharmaphorum.com/news/bms-2/
BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
